CEO Bill Sibold's total reported compensation of $19.2 million is elevated for a biotech CEO at MDGL's current market cap, but the company delivered exceptional commercial results in 2025 — $958 million in Rezdiffra revenue (a 432% year-over-year increase) — and the 3-year stock return of +68.9% outperforms the XBI (SPDR S&P Biotech ETF) by +8.2 percentage points, demonstrating that above-benchmark incentive pay is aligned with shareholder outcomes. The pay structure is well-designed: approximately two-thirds of executive compensation is variable and performance-linked (stock options that only have value if the stock price rises, and performance stock awards tied to relative total shareholder return versus the Nasdaq Biotechnology Index over a three-year period), the company has a meaningful compensation clawback policy, and shareholders gave 99% support in 2025, affirming broad satisfaction with the program.

Non-audit fees (tax fees of $285,994 plus other fees of $3,000 totaling $288,994) represent approximately 19.7% of audit fees of $1,468,100, well below the 50% threshold that would raise independence concerns; PwC is a Big 4 firm appropriate for a company of MDGL's size and complexity; auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire and a FOR vote applies by policy; no material restatements were identified.